Moreover, dual targeting of PRMT5 and the PI3K/mTOR or MEK/ERK pathways enhances anti-tumor efficacy, supporting the development of biomarker-guided combination strategies to improve therapeutic outcomes in CRC [36,37,38]. This evidence concerns the gene PRMT5 and colorectal carcinoma.